Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neoplasm Metastasis × RRx-001 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Lymphoma 3 Stomatitis 2 Small Cell Lung Carcinoma 2 Neoplasms 2 Mucositis 2 Mouth Neoplasms 2 Lung Neoplasms 2 Head and Neck Neoplasms 2 Carcinoma, Small Cell 2 Brain Neoplasms 2 Spinal Cord Neoplasms 1 Neuroendocrine Tumors 1 Neoplasm Metastasis 1 Cholangiocarcinoma 1 Central Nervous System Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 128 Gemcitabine 115 Capecitabine 107 Fluorouracil 99 Paclitaxel 98 Bevacizumab 91 Oxaliplatin 89 Nivolumab 84 Leucovorin 81 Docetaxel 77 Radiosurgery 74 Irinotecan 72 Cisplatin 69 Carboplatin 69 Cyclophosphamide 60 Magnetic Resonance Spectroscopy 59 Cetuximab 59 Biopsy 51 Specimen Handling 50 Trastuzumab 46 Radiotherapy 44 Ipilimumab 43 Pemetrexed 38 Everolimus 38 Drug Therapy 38 Albumin-Bound Paclitaxel 36 130-nm albumin-bound paclitaxel 36 Fulvestrant 34 Doxorubicin 34 aldesleukin 32

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02801097 2022-05-17

PAYLOAD

EpicentRx, Inc.

Phase 1 Terminated

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡